Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2026	Sep. 30, 2025
Operating activities:
Net income	$ 67,427	$ 61,832
Loss (income) from discontinued operations	4,055	(770)
Income from continuing operations	71,482	61,062
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation	8,181	8,293
Amortization of operating lease assets	7,018	7,216
Depreciation	10,862	10,296
Amortization of acquired intangible assets	1,394	2,805
Amortization and write-off of debt discount and issuance costs	660	1,145
Provision for credit losses	22,402	14,883
Deferred income taxes	8,798	54,413
Loss on disposals and impairments of property and equipment		2
Loss (gain) on investments	218	(680)
Changes in assets and liabilities:
Accounts and financing receivables	(94,219)	(62,690)
Prepaid expenses and other current assets	(10,788)	(29,841)
Cloud computing implementation assets	(3,292)	(4,812)
Accounts payable	(13,536)	1,378
Accrued payroll and benefits	(20,886)	(24,359)
Accrued liabilities	13,025	(12,287)
Deferred revenue	107,928	109,082
Operating lease liabilities	10,548	(4,317)
Other assets and liabilities	(5,524)	(960)
Net cash provided by operating activities-continuing operations	114,271	130,629
Net cash used in operating activities-discontinued operations	(233)	(80)
Net cash provided by operating activities	114,038	130,549
Investing activities:
Capital expenditures	(37,592)	(16,023)
Proceeds from sales of marketable securities		100
Purchases of marketable securities		(100)
Net cash used in investing activities	(37,592)	(16,023)
Financing activities:
Proceeds from exercise of stock options		131
Employee taxes paid on withholding shares	(16,203)	(39,119)
Proceeds from stock issued under Colleague Stock Purchase Plan	564	411
Repurchases of common stock for treasury	(81,002)	(7,595)
Repayments under long-term debt obligations	(163,000)	0
Payment of debt issuance costs		(3,333)
Net cash used in financing activities	(259,641)	(49,505)
Net (decrease) increase in cash, cash equivalents and restricted cash	(183,195)	65,021
Cash, cash equivalents and restricted cash at beginning of period	407,754	201,164
Cash, cash equivalents and restricted cash at end of period	224,559	266,185
Non-cash investing and financing activities:
Accrued capital expenditures	17,969	4,727
Accrued liability for repurchases of common stock	3,000	0
Accrued excise tax on share repurchases	$ 2,310	1,630
Accrued debt issuance costs		$ 437